Novartis IndiaBOM:500672 +0.17%59 Net Margin % is 27.89% as of Mar. 2026, which is 109% above its 10-year median of 13.33. GuruFocus rates BOM:500672 with a GF Score™ of 59/100 and a GF Value™ of ₹928.24 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 953 Drug Manufacturers companies, Novartis India ranks better than 92.65% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Novartis India's Net Income for the
three
months ended in Mar. 2026 was ₹253 Mil. Novartis India's Revenue for the
three
months ended in Mar. 2026 was ₹906 Mil. Therefore, Novartis India's net margin for the quarter that ended in Mar. 2026 was 27.89%.
The historical rank and industry rank for Novartis India's Net Margin % or its related term are showing as below:
BOM:500672'
s Net Margin % Range Over the Past 10 Years
Min: -0.96 Med: 13.33 Max: 28.32
Current: 26.3
BOM:500672's Net Margin % is ranked better than 92.65% of 953
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs BOM:500672: 26.30
Novartis India (BOM:500672) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Novartis India Net Margin % Related Terms
Novartis India Net Margin % Historical Data
* Premium members only.
The historical data trend for Novartis India's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Novartis India's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novartis India Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novartis India's Net Margin % distribution charts can be found below:
* The bar in red indicates where Novartis India's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novartis India (BOM:500672) has a Net Margin % of 27.89% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Novartis India and its competitors. This is 109% above median its historical median of 13.33. According to the industry distribution chart, Novartis India ranks #70 out of 953 companies in the Drug Manufacturers industry, placing it in the top 7.3%.
Is Novartis India's Net Margin % too high?
Novartis India's current Net Margin % of 27.89% is 109% above median its 10-year median of 13.33. The Drug Manufacturers industry median Net Margin % is 5.69. Novartis India's value of 27.89% is 390.2% above this industry median. Based on the distribution chart, Novartis India ranks #70 out of 953 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novartis India has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis India's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Novartis India ranks #70 out of 953 companies for Net Margin %. This places Novartis India in the top 7% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.69. Novartis India's value of 27.89% is 390.2% above this benchmark. While the company's 10-year median is 13.33 vs. the industry median of 5.69, Novartis India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novartis India's current Net Margin % of 27.89% is 390.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Novartis India and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novartis India's current Net Margin % is 27.89%, which is 109% above median its own 10-year median of 13.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis India stock overvalued right now?
Based on GuruFocus' analysis, Novartis India (BOM:500672) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹928.24, compared to a current price of ₹1,440.95 — trading 55.2% above its estimated fair value. The current Net Margin % is 27.89%, which is 109% above median its 10-year median of 13.33 and 390.2% above the Drug Manufacturers industry median of 5.69. Novartis India's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Novartis India (BOM:500672), the current Net Margin % is 27.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novartis India (BOM:500672) Overvalued in 2026?
Based on GuruFocus' analysis, Novartis India stock appears to be overvalued.
The current stock price of ₹1,440.95 is trading 55.2% above its estimated GF Value™ of ₹928.24.
GuruFocus considers Novartis India to be Significantly Overvalued.
Key valuation signals for BOM:500672:
Net Margin %: 27.89% (109% above median its 10-year median of 13.33)
GF Value™: ₹928.24 vs. price of ₹1,440.95 (55.2% above fair value)
Industry Position: 390.2% above the Drug Manufacturers median (#70 of 953)
No single metric tells the full story. See the BOM:500672 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.
59GF Score
Get the complete analysis for BOM:500672
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500672 has been successfully added to your 
